Compare Enveric Biosciences Inc (ENVB) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Msci Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Msci Inc trades at $562.19 (market cap $40.38B). The key difference: Msci Inc is far larger — about 6035.9× Enveric Biosciences Inc's market cap, and Msci Inc pays a 1.48% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Msci Inc for 82 Days on average.
| ENVB | MSCI | |
|---|---|---|
Market Cap | $6.69M | $40.38B |
Volume | 41,141 | 414,140 |
Sector | Health | Financials |
52-Week High | $10.80 | $643.83 |
52-Week Low | $1.27 | $511.84 |
Typical Hold Time | 14 Days | 82 Days |
Enterprise Value | -$1.60M | $46.54B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
MSCI trades at $555.38, up 0.08% with neutral technical signals. The company demonstrates strong fundamentals with 2025 revenue of $3.13B and net income margin of 40.73%. Recent Q2 2026 earnings slightly missed expectations at $4.94 EPS versus $4.99 expected, though Q1 and Q4 2025 beat estimates. Analyst consensus remains strongly bullish with 74% buy ratings and $701.71 price target, representing 26% upside potential. The stock shows consistent revenue growth from $2.2B in 2022 to $3.1B in 2025.
MSCI presents a compelling investment case with premium valuation (P/E 30.37) justified by strong profitability and market leadership. Key risks include high debt levels ($4.51B long-term debt) and competitive pressures in financial data services. The upcoming Q3 2026 earnings report on October 20, 2026, will be crucial for validating growth trajectory. Institutional sentiment remains positive given the company's recurring revenue model and expansion into climate risk analytics through the First Street acquisition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
